Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s176. https://doi.org/10.25251/skin.7.supp.176